Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line...
8 insider purchases on record · latest filing 2026-06-23.
Insiders have also filed 2 sale transactions at TPST.